Nova Mentis Life Science (Nova Mentis Life Science) Change In Receivables : $0.07 Mil (TTM As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Change In Receivables?

Nova Mentis Life Science's change in receivables for the quarter that ended in Sep. 2023 was $0.00 Mil. It means Nova Mentis Life Science's Accounts Receivable stayed the same from Mar. 2023 to Sep. 2023 .

Nova Mentis Life Science's change in receivables for the fiscal year that ended in Dec. 2022 was $0.05 Mil. It means Nova Mentis Life Science's Accounts Receivable declined by $0.05 Mil from Dec. 2021 to Dec. 2022 .

Nova Mentis Life Science's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nova Mentis Life Science's Days Sales Outstanding for the three months ended in Sep. 2023 was 21.73.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nova Mentis Life Science's liquidation value for the three months ended in Sep. 2023 was $-0.46 Mil.

Nova Mentis Life Science Change In Receivables Historical Data

The historical data trend for Nova Mentis Life Science's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Change In Receivables Chart

Nova Mentis Life Science Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.01

0.05

-0.01

-0.04

0.05

Nova Mentis Life Science Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-	0.06	-	-	-

Nova Mentis Life Science Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.

Nova Mentis Life Science (OTCPK:NMLSF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nova Mentis Life Science's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.005	/	0.021	*	91
=	21.73

2. In Ben Graham's calculation of liquidation value, Nova Mentis Life Science's accounts receivable are only considered to be worth 75% of book value:

Nova Mentis Life Science's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.018	-	0.484	+	0.75 * 0.005	+	0.5 * 0
=	-0.46

Nova Mentis Life Science Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

HN3Q:Germany NOVA:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.